Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Weekly News Recap #Phispers
1. Act-132577
2. N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)sulfuric Diamide
3. Sulfamide, N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-
1. 1103522-45-7
2. Act-132577
3. Aprocitentan [usan]
4. Macitentan Metabolite M6
5. Mzi81hv01p
6. 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine
7. Chembl2165326
8. Chebi:76609
9. N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfuric Diamide
10. N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]sulfamide
11. Sulfamide, N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-
12. Despropyl Macitentan
13. N-despropyl-macitentan
14. Unii-mzi81hv01p
15. N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)sulfamide
16. N-(5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)sulfuric Diamide
17. Act 132577
18. Aprocitentan (usan/inn)
19. Aprocitentan [inn]
20. Schembl3646065
21. Aprocitentan (act-132577)
22. Gtpl10070
23. Amy39078
24. Bcp28125
25. Ex-a4419
26. Bdbm50395672
27. Who 10552
28. Zinc95553608
29. Db15059
30. Ncgc00378592-01
31. Ac-36529
32. As-82256
33. Hy-15895
34. Db-130379
35. D11441
36. D87138
37. A922313
38. Q27146161
39. Act-132577; Act 132577; Act132577
40. 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine.
41. N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-sulfamide
42. N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)sulfuric Diamide
43. N-(5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)sulfamide
Molecular Weight | 546.2 g/mol |
---|---|
Molecular Formula | C16H14Br2N6O4S |
XLogP3 | 2.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 8 |
Exact Mass | 545.91435 g/mol |
Monoisotopic Mass | 543.91640 g/mol |
Topological Polar Surface Area | 151 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 597 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of hypertension
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Maithri Drugs: Delivering Trusted, High-Quality APIs to 35+ Countries with Innovation, Compliance, and Excellence.
Details:
Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension.
Lead Product(s): Aprocitentan,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2025
Lead Product(s) : Aprocitentan,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Approves an Updated Label for TRYVIO (aprocitentan) Removing the REMS Requirement
Details : Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2025
Details:
Undisclosed
Lead Product(s): Ethinyl Estradiol,Levonorgestrel,Aprocitentan
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 29, 2025
Lead Product(s) : Ethinyl Estradiol,Levonorgestrel,Aprocitentan
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 29, 2025
Details:
Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension in adult patients, in combination with other antihypertensive drugs.
Lead Product(s): Aprocitentan,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 15, 2024
Lead Product(s) : Aprocitentan,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Idorsia Launches TRYVIO™ in the U.S. for Hard-to-Control Hypertension
Details : Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension in adult patients, in combination with other antihypertensive drugs.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2024
Details:
Jeraygo (aprocitentan), the first endothelin receptor antagonist, treats hypertension in adults by combining it with other antihypertensives to reduce blood pressure.
Lead Product(s): Aprocitentan,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jeraygo
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 26, 2024
Lead Product(s) : Aprocitentan,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
JERAYGO Recommended for Approval in Europe for Resistant Hypertension Treatment
Details : Jeraygo (aprocitentan), the first endothelin receptor antagonist, treats hypertension in adults by combining it with other antihypertensives to reduce blood pressure.
Product Name : Jeraygo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2024
Details:
Tryvio (aprocitentan), an endothelin receptor antagonist, is indicated for treating hypertension when combined with other antihypertensives to lower blood pressure in adults.
Lead Product(s): Aprocitentan,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2024
Lead Product(s) : Aprocitentan,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Approves Idorsia's TRYVIO As First Endothelin Antagonist for High Blood Pressure
Details : Tryvio (aprocitentan), an endothelin receptor antagonist, is indicated for treating hypertension when combined with other antihypertensives to lower blood pressure in adults.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2024
Details:
Idorsia will reacquire the development and commercialization rights for aprocitentan, a potential novel, effective, once-daily, orally active, dual endothelin A and B receptor antagonist and well-tolerated treatment for resistant hypertension, from Janssen.
Lead Product(s): Aprocitentan,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Idorsia Pharmaceuticals
Deal Size: $343.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 09, 2023
Lead Product(s) : Aprocitentan,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Idorsia Pharmaceuticals
Deal Size : $343.0 million
Deal Type : Licensing Agreement
Idorsia Reacquires the World-Wide Rights to Aprocitentan
Details : Idorsia will reacquire the development and commercialization rights for aprocitentan, a potential novel, effective, once-daily, orally active, dual endothelin A and B receptor antagonist and well-tolerated treatment for resistant hypertension, from Janss...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 09, 2023
Details:
ACT-132577 (aprocitentan) is a dual endothelin receptor antagonist, which potently inhibits the binding of ET-1 to ETA and ETB receptors. It has a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.
Lead Product(s): Aprocitentan,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: JANSSEN BIOTECH
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 31, 2023
Lead Product(s) : Aprocitentan,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : JANSSEN BIOTECH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-132577 (aprocitentan) is a dual endothelin receptor antagonist, which potently inhibits the binding of ET-1 to ETA and ETB receptors. It has a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2023
Details:
ACT-132577 (aprocitentan), is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors.
Lead Product(s): Aprocitentan,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2022
Lead Product(s) : Aprocitentan,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-132577 (aprocitentan), is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Details:
Aprocitentan (ACT-132577), a novel, dual ERA, which potently inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is intended to address the pathophysiology of difficult-to-control HTN.
Lead Product(s): Aprocitentan,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Idorsia Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 11, 2022
Lead Product(s) : Aprocitentan,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Idorsia Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aprocitentan (ACT-132577), a novel, dual ERA, which potently inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is intended to address the pathophysiology of di...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2022
Details:
ACT-132577 (aprocitentan) reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concerns.
Lead Product(s): Aprocitentan,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2022
Lead Product(s) : Aprocitentan,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-132577 (aprocitentan) reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concerns.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
5-(4-Bromophenyl)-4,6-dichloropyrimidine
CAS Number : 146533-41-7
End Use API : Aprocitentan
About The Company : Glenfin Chemicals, a trusted provider of high-quality chemical solutions tailored to meet the diverse needs of industries worldwide. Based in the heart of inno...
Regulatory Info : RX
Registration Country : USA
Brand Name : TRYVIO
Dosage Form : TABLET;ORAL
Dosage Strength : 12.5MG
Packaging :
Approval Date : 2024-03-19
Application Number : 217686
Regulatory Info : RX
Registration Country : USA
RLD : Yes
TE Code :
Brand Name : TRYVIO
Dosage Form : TABLET;ORAL
Dosage Strength : 12.5MG
Approval Date : 2024-03-19
Application Number : 217686
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
https://www.pharmacompass.com/pipeline-prospector-blog/march-sees-approvals-of-pathbreaking-nash-drug-from-madrigal-two-meds-for-pah
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
41
PharmaCompass offers a list of Aprocitentan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Aprocitentan manufacturer or Aprocitentan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Aprocitentan manufacturer or Aprocitentan supplier.
PharmaCompass also assists you with knowing the Aprocitentan API Price utilized in the formulation of products. Aprocitentan API Price is not always fixed or binding as the Aprocitentan Price is obtained through a variety of data sources. The Aprocitentan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Aprocitentan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aprocitentan, including repackagers and relabelers. The FDA regulates Aprocitentan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aprocitentan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Aprocitentan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Aprocitentan supplier is an individual or a company that provides Aprocitentan active pharmaceutical ingredient (API) or Aprocitentan finished formulations upon request. The Aprocitentan suppliers may include Aprocitentan API manufacturers, exporters, distributors and traders.
click here to find a list of Aprocitentan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Aprocitentan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aprocitentan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aprocitentan GMP manufacturer or Aprocitentan GMP API supplier for your needs.
A Aprocitentan CoA (Certificate of Analysis) is a formal document that attests to Aprocitentan's compliance with Aprocitentan specifications and serves as a tool for batch-level quality control.
Aprocitentan CoA mostly includes findings from lab analyses of a specific batch. For each Aprocitentan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aprocitentan may be tested according to a variety of international standards, such as European Pharmacopoeia (Aprocitentan EP), Aprocitentan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aprocitentan USP).